Drugs & Aging

, Volume 31, Issue 3, pp 193–201

Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands

  • Job F. M. van Boven
  • Annoesjka Novak
  • Maurice T. Driessen
  • Cornelis Boersma
  • Maarten M. Boomsma
  • Maarten J. Postma
Short Communication

Abstract

Background

By using the findings obtained from the PREPARED study, we aimed to estimate the cost effectiveness of ropinirole prolonged release (PR) [Requip-Modutab®] in Parkinson’s disease (PD) versus ropinirole immediate release (IR). In the PREPARED study, ropinirole PR provided a significantly greater improvement in time spent ‘off’ than ropinirole IR when used as an add-on to levodopa.

Methods

A health state transition model was developed—based on Hoehn and Yahr (HY) stages in PD—to compare the two treatment strategies. The Markov model included the following treatment-related aspects: (i) rate of disease progression; (ii) rates of dyskinesia; and (iii) medication adherence.

Results

In our approach, the base-case analysis showed a favourable pharmacoeconomic profile of ropinirole PR versus ropinirole IR. In particular, general cost savings were estimated combined with modest gains in quality of life, due to reduced disease progression and lower dyskinesia rates. Sensitivity analyses showed that this result was rather robust for varying parameters deterministically, although cost savings were lost in some instances. In particular, the treatment benefits of lower dyskinesia rates and improved adherence influenced the cost-effectiveness outcome. Nonetheless, the cost effectiveness remained acceptable within the limits that were investigated. Probabilistic sensitivity analysis revealed that the probability of accepting PR over IR exceeded 95 % for all relevant ‘willingness-to-pay’ thresholds.

Conclusion

The results of our study indicate a high likelihood of ropinirole PR being cost saving or at least being considered cost effective for use in the Netherlands. However, claims included in our model regarding dyskinesia and improved medication adherence should be further supported by data from daily practice.

References

  1. 1.
    Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Weintraub D, Comella CL, Horn S. Parkinson’s disease—part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008;14:S40–8.PubMedGoogle Scholar
  3. 3.
    Klotsche J, Reese JP, Winter Y, Oertel WH, Irving H, Wittchen HU, Rehm J, Dodel R. Trajectory classes of decline in health-related quality of life in Parkinson’s disease: a pilot study. Value Health. 2011;14:329–38.PubMedCrossRefGoogle Scholar
  4. 4.
    Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Botzel K, Oertel WH, Dodel R, Poewe W. Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study. J Neurol. 2010;257:638–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Bloem BR, Van Laar T, Keus SHJ, De Beer H, Poot E, Buskens E, Aarden W, Munneke M, on behalf of the Centrale Werkgroep Multidisciplinaire Richtlijn Parkinson 2006–2009. Multidisciplinaire richtlijn ziekte van Parkinson [in Dutch]. http://www.cbo.nl/Downloads/880/rl_parkinson_10.pdf. Accessed 5 Aug 2010.
  6. 6.
    de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.PubMedCrossRefGoogle Scholar
  7. 7.
    de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. J Neurol Neurosurg Psychiatry. 1997;62:10–5.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63:1240–4.PubMedCrossRefGoogle Scholar
  9. 9.
    de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62:1265–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Shulman LM, Gruber-Baldini AL, Anderson KE, Vaughan CG, Reich SG, Fishman PS, Weiner WJ. The evolution of disability in Parkinson disease. Mov Disord. 2008;23:790–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O’Brien CF. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology. 1997;49:393–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology. 1998;51:1057–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342:1484–91.PubMedCrossRefGoogle Scholar
  17. 17.
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.PubMedCrossRefGoogle Scholar
  18. 18.
    Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord. 2010;25:858–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26:1259–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20:617–28.PubMedCrossRefGoogle Scholar
  21. 21.
    Health Care Insurance Board. Dutch pharmacoeconomic guidelines [in Dutch]. http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rubriek+zorgpakket/cfh/richtlijnen+farmaco-economisch+onderzoek+-+engels.pdf (2004). Accessed 30 Dec 2011.
  22. 22.
    Oostenbrink JB, Bouwmans CAM, Koopmanschap MA. Guideline for costing research, methods and standardized prices for economic evaluations in health care [in Dutch]. 2004.Google Scholar
  23. 23.
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http://www.ispor.org/peguidelines/index.asp. Date last accessed: 30 Dec 2011.
  24. 24.
    Nuijten MJ, van Iperen P, Palmer C, van Hilten BJ, Snyder E. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health. 2001;4:316–28.PubMedCrossRefGoogle Scholar
  25. 25.
    Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, Gerstner A, Berger K, Hellwig D, Deuschl G, Freund HJ, Oertel WH, Dodel RC. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol. 2002;249:759–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Smala AM, Spottke EA, Machat O, Siebert U, Meyer D, Kohne-Volland R, Reuther M, DuChane J, Oertel WH, Berger KB, Dodel RC. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord. 2003;18:898–905.PubMedCrossRefGoogle Scholar
  27. 27.
    Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson’s disease. Value Health. 2004;7:610–26.PubMedCrossRefGoogle Scholar
  28. 28.
    Hudry J, Rinne JO, Keranen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006;40:651–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U, Hagell P. Estimating the value of novel interventions for Parkinson’s disease: an early decision-making model with application to dopamine cell replacement. Parkinsonism Relat Disord. 2006;12:443–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Eggert KM, Reese JP, Oertel WH, Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson’s disease. CNS Drugs. 2008;22:841–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13:397–409.PubMedCrossRefGoogle Scholar
  32. 32.
    Postma MJ, Boersma C. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson’s disease. Expert Rev Clin Pharmacol. 2012;5:1–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Bala MV, Mauskopf JA. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts. Pharmacoeconomics. 2006;24:345–54.PubMedCrossRefGoogle Scholar
  34. 34.
    Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C, LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E. RGS9-2 negatively modulates l-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson’s disease. J Neurosci. 2007;27:14338–48.PubMedCrossRefGoogle Scholar
  35. 35.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson’s disease: progression and mortality in the l-DOPA era. Adv Neurol. 1996;69:3–11.PubMedGoogle Scholar
  36. 36.
    Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Qual Life Res. 2000;9:819–27.PubMedCrossRefGoogle Scholar
  37. 37.
    Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70:1423–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Herlofson K, Lie SA, Arsland D, Larsen JP. Mortality and Parkinson disease: a community based study. Neurology. 2004;62:937–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health. 2001;4:308–15.PubMedCrossRefGoogle Scholar
  41. 41.
    Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology. 2001;56:S1–88.PubMedCrossRefGoogle Scholar
  42. 42.
    Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ. 2000;321:21–2.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I. Cascade of levodopa dose and weight-related dyskinesia in Parkinson’s disease (LD-WD-PD cascade). Parkinsonism Relat Disord. 2006;12:499–505.PubMedCrossRefGoogle Scholar
  44. 44.
    Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics. 2005;23:817–36.PubMedCrossRefGoogle Scholar
  45. 45.
    Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M, Trial Study Group. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12:956–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Ara R, Brazier J. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12:346–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci. 2000;23:S109–15.PubMedCrossRefGoogle Scholar
  48. 48.
    Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord. 2010;25:474–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord. 2005;20:1502–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson’s disease. Mov Disord. 2008;23:359–65.PubMedCrossRefGoogle Scholar
  51. 51.
    College of Health Insurance Companies (College voor Zorgverzekeringen). http://www.medicijnkosten.nl. Date last accessed: 16 July 2010.
  52. 52.
    Munneke M, Nijkrake MJ, Keus SH, Kwakkel G, Berendse HW, Roos RA, Borm GF, Adang EM, Overeem S, Bloem BR, ParkinsonNet Trial Study Group. Efficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trial. Lancet Neurol. 2010;9:46–54.PubMedCrossRefGoogle Scholar
  53. 53.
    ParkinsonNet. http://www.parkinsonnet.nl. Date last accessed: 15 July 2011.
  54. 54.
    College of Health Insurance Companies. (College voor Zorgverzekeringen). http://www.gipdatabank.nl. Date last accessed: 30 December 2011.
  55. 55.
    Briggs AH, Claxton K, Sculpher MJ, editors. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.Google Scholar
  56. 56.
    Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson’s disease. Mov Disord. 2006;21:616–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Haycox A, Armand C, Murteira S, Cochran J, Francois C. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluation. Drugs Aging. 2009;26:791–801.PubMedCrossRefGoogle Scholar
  58. 58.
    Hoerger TJ, Bala MV, Rowland C, Greer M, Chrischilles EA, Holloway RG. Cost effectiveness of pramipexole in Parkinson’s disease in the US. Pharmacoeconomics. 1998;14:541–57.PubMedCrossRefGoogle Scholar
  59. 59.
    Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S, NINDS NET-PD Investigators and Coordinators. Self-reported adherence versus pill count in Parkinson’s disease: the NET-PD experience. Mov Disord. 2007;22:822–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord. 2004;19:513–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Job F. M. van Boven
    • 1
  • Annoesjka Novak
    • 2
  • Maurice T. Driessen
    • 3
  • Cornelis Boersma
    • 1
    • 3
  • Maarten M. Boomsma
    • 3
  • Maarten J. Postma
    • 1
  1. 1.Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics (PE2)University of GroningenGroningenThe Netherlands
  2. 2.Anovak ServicesApeldoornThe Netherlands
  3. 3.GlaxoSmithKlineZeistThe Netherlands

Personalised recommendations